Fibrate therapy in patients with metabolic syndrome and diabetes mellitus

被引：13

作者：

Dayspring T. ^{[1
]}

Pokrywka G. ^{[1
]}

机构：

[1] North Jersey Institute of Menopausal Lipidology, Wayne, NJ 07470

来源：

Current Atherosclerosis Reports | 2006年 / 8卷 / 5期

关键词：

Statin; Ezetimibe; Arterioscler Thromb Vasc Biol; Fibrate Therapy; Diabetes Atherosclerosis Intervention Study;

D O I：

10.1007/s11883-006-0032-x

中图分类号：

学科分类号：

摘要：

Patients with metabolic syndrome and type 2 diabetes mellitus are usually in moderately high-risk, high-risk, or very high-risk cardiovascular categories and present major therapeutic challenges. The dyslipidemia in such patients is typically a disorder of the triglyceride/high-density lipoprotein axis (TG/HDL axis) characterized by an excess of triglyceride-rich lipoproteins and a reduction of HDL. Very often, lifestyle therapy and statin monotherapy fail to achieve guideline goals, necessitating combination therapies. Fibric acids (or fibrates), are agonists of peroxisome proliferator-activated receptor α, which have amassed significant lipid-surrogate and clinical outcome trial data, especially in insulin-resistant patients, typical of those with metabolic syndrome or type 2 diabetes mellitus. Current guidelines advocate fibrate use as an add-on to statin therapy when TG/HDL abnormalities exist in such patients. In this paper, we review pertinent and recent trial data, mechanisms of action, and the safety of fibrate therapy. Copyright © 2006 by Current Science Inc.

引用

页码：356 / 364

页数：8

共 71 条

[51]

Chinetti G., Lestavel S., Bocher V., Et al., PPAR-a and PPAR-a activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway, Nat Med, 7, pp. 53-58, (2001)

[52]

Li A.C., Palinsk W., Peroxisome proliferator-activated receptors: How their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis, Annu Rev Pharmacol Toxicol, 46, pp. 1-39, (2006)

[53]

Nigon F., Lesnik P., Rouis M., Et al., Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor, J Lipid Res, 32, pp. 1741-1753, (1991)

[54]

Despres J.P., Lemieux I., Robins S.J., Role of fibric acid derivatives in the management of risk factors for coronary heart disease, Drugs, 64, pp. 2177-2198, (2004)

[55]

Tenenbaum A., Motrol M., Fisman E.Z., Et al., Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients, Eur Heart J, 26, pp. 2032-2038, (2005)

[56]

Koh K.K., Han F.S., Quon M.J., Et al., Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia, Diabetes Care, 28, pp. 1419-1424, (2005)

[57]

Wysocki J., Belowski D., Kalina M., Et al., Effect of micronized fenofibrate on insulin resistance in patients with metabolic syndrome, Int J Clin Pharmacol, 42, pp. 212-217, (2004)

[58]

Li A.C., Glass C.K., PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis, J Lipid Res, 45, pp. 2161-2173, (2004)

[59]

Koh K.K., Ahn J.Y., Han S.H., Et al., Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis, Atherosclerosis, 174, pp. 379-383, (2004)

[60]

Chinetti-Gbaguida G., Fruchart J.C., Staeils B., Pleiotropic effects of fibrates, Curr Atheroscler Rep, 7, pp. 396-401, (2005)

← 1 2 3 4 5 6 7 8 →